FibroBiologics, Inc. financial data

Symbol
FBLG on Nasdaq
Industry
Pharmaceutical Preparations
Location
455 E. Medical Center Blvd, Suite 300, Houston, TX
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 87 %
Debt-to-equity -6.17K %
Return On Equity 5.74K %
Return On Assets -94.5 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.7M shares +15.6%
Entity Public Float 147M USD
Weighted Average Number of Shares Outstanding, Basic 32.9M shares +16.5%
Weighted Average Number of Shares Outstanding, Diluted 32.9M shares +16.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.5M USD +90.2%
General and Administrative Expense 9.23M USD +41.6%
Operating Income (Loss) -13.7M USD -54.5%
Nonoperating Income (Expense) 2.85M USD
Net Income (Loss) Attributable to Parent -11.2M USD +32.3%
Earnings Per Share, Basic -0.34 USD/shares +50%
Earnings Per Share, Diluted -0.34 USD/shares +50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14M USD +52.6%
Other Assets, Current 18K USD +12.5%
Assets, Current 14.2M USD +54.4%
Property, Plant and Equipment, Net 824K USD +3.39%
Operating Lease, Right-of-Use Asset 1.39M USD -23%
Assets 16.4M USD +39.1%
Contract with Customer, Liability, Current 241K USD
Liabilities, Current 12.7M USD +38.6%
Operating Lease, Liability, Noncurrent 984K USD -29%
Liabilities 13.7M USD +29.7%
Retained Earnings (Accumulated Deficit) -35.5M USD -45.8%
Stockholders' Equity Attributable to Parent 2.74M USD +118%
Liabilities and Equity 16.4M USD +39.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.28M USD -110%
Net Cash Provided by (Used in) Financing Activities 3.28M USD -77.5%
Net Cash Provided by (Used in) Investing Activities -8K USD +85.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.01M USD -108%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 14M USD +52.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4K USD
Deferred Tax Assets, Valuation Allowance 5.26M USD +79.1%
Deferred Tax Assets, Gross 5.68M USD +70.7%
Operating Lease, Liability 1.39M USD -20.7%
Depreciation 157K USD +234%
Payments to Acquire Property, Plant, and Equipment 8K USD -85.7%
Lessee, Operating Lease, Liability, to be Paid 1.54M USD -23.6%
Property, Plant and Equipment, Gross 1.03M USD +21.8%
Operating Lease, Liability, Current 401K USD +10.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 544K USD +11.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 487K USD +2.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 155K USD -42.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 509K USD -6.43%
Deferred Tax Assets, Operating Loss Carryforwards 3.61M USD +80.2%
Preferred Stock, Shares Authorized 10M shares -50%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 509K USD
Additional Paid in Capital 38.3M USD +49.4%
Share-based Payment Arrangement, Expense 2.22M USD +25.7%
Interest Expense 5K USD -50%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%